Plasma exosome-derived fragile site-associated tumor suppressor as a powerful prognostic predictor for patients with ovarian cancer. Biomol Biomed [Internet]. 2022 Jun. 1 [cited 2024 Apr. 29];22(3):453-9. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/6404